Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Immunim
- Development stage
- Unknown
- Lead developer
- Centre for Plant Medicine Research
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
**Immunim** (also known as **CPM-01** or **CPM01**) is a standardized herbal tincture developed by the **Centre for Plant Medicine Research** (CPMR) in Ghana. It is a hydroethanolic extract prepared from the dried leaves of *Azadirachta indica* (neem). Originally developed as an immunomodulatory agent and immune system support supplement, Immunim has been registered by the Ghana Foods and Drugs Authority (FDA) for the management of COVID-19 symptoms and to expedite patient recovery. In vitro studies have demonstrated that CPM-01 and its fractions exhibit potent anti-SARS-CoV-2 activity, specifically inhibiting the viral ORF3a protein and preventing virus-induced cytopathic effects. Ongoing pharmaceutical development includes the formulation of the tincture into a standardized tablet dosage form to improve patient compliance and consistency.
- Brand names
- Immunim
- Other names
- Azadirachta indica leaf extractAzadirachta indica tinctureneem leaf extractneem tincture
02
Targets
ORF3a (SARS-CoV-2 ORF3a protein)
Beyond the preview
Go deeper on Immunim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunim.